We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Idiotypic Vaccination for Follicular Lymphoma Patients (FLIDVAX2006)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00530140
Recruitment Status : Unknown
Verified October 2011 by Clinica Universidad de Navarra, Universidad de Navarra.
Recruitment status was:  Recruiting
First Posted : September 17, 2007
Last Update Posted : October 6, 2011
Sponsor:
Collaborators:
University of Navarrra Hospital (Clinica Universitaria)
Center for Applied Medical Research (Centro de Investigación Médica Aplicada)
Information provided by (Responsible Party):
Clinica Universidad de Navarra, Universidad de Navarra

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Poor prognosis follicular lymphoma patients have an estimated median overall survival of 5-6 years. The proposed trial offers life-time idiotypic vaccination to all such patients in first relapse/progression who will achieve second (first, in the case of patients who have never achieved complete response following standard first-line treatment) complete response through autologous stem cell transplant prior to vaccination start. The ultimate goal is a cure, defined as a vaccine-maintained complete response lasting both at least 10 years and at least twice as long as each patient's first complete response.

Condition or disease Intervention/treatment Phase
Follicular Lymphoma First Relapse/Progression Biological: Follicular lymphoma, patient-specific, soluble protein idiotype vaccine Phase 2

Detailed Description:
Idiotypic vaccination has already proved capable (in responding patients) of: biological efficacy, that is the capacity of inducing an idiotype- and tumor-specific immune response (Kwak LW et al. NEJM 1992); clinical efficacy, that is the capacity of inducing specific immune responses able to kill in vivo follicular lymphoma cells that had survived pre-vaccine chemotherapy (Bendandi M et al. Nature Med 1999): clinical benefit, that is the capacity of prolonging survival of responding patients (Inoges et al. JNCI 2006). Now, we want to test whether it is also capable of contributing to the ultimate goal of preventing relapse indefinitely in responding patients.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Idiotypic Vaccination for Poor-prognosis Follicular Lymphoma Patients in First Relapse
Study Start Date : October 2007
Estimated Primary Completion Date : September 2013
Estimated Study Completion Date : September 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma Vaccines

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: A
All patients will receive the same vaccination schedule/formulation
 Biological: Follicular lymphoma, patient-specific, soluble protein idiotype vaccine
0.5 mg of idiotype conjugated to 0.5 mg of KLH + 125 mcg of GM-CSF 5 monthly vaccinations followed by 3 bi-monthly vaccinations, followed by one boost every three months until either relapse or death from cause unrelated to lymphoma


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of patients who both never relapse and have a second complete response longer than their first response (cured) [ Time Frame: 15 years ]

Secondary Outcome Measures :
  1. Percentage of patients who successfully maintain a measurable, specific immune response throughout the active vaccination time frame [ Time Frame: 15 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: at least one of the following:

  • FLIPI score 3 thru 5 at diagnosis and/or at relapse
  • First complete response shorter than 3 years, if no maintenance (Interferon, Rituximab, etc) treatment was administered, or than 5 years if maintenance treatment was administered
  • No treatment has been able to induce complete response until autologous stem cell transplant
  • Poor-prognosis genomic profiling

Exclusion Criteria: any of the following:

  • Unavailability of a harvestable lymph node of at least cm 2x2x2
  • Life expectancy < 1 year
  • Abnormal heart or liver or kidney function
  • ECOG Performance Status > 2
  • Failure to sign informed consent before enrollment
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00530140


Contacts
Layout table for location contacts
Contact: MAURIZIO BENDANDI, MD, PhD +34606002087 mbendandi@unav.es
Contact: SUSANA INOGES, MD, PhD +34685972257 sinoges@unav.es

Locations
Layout table for location information
Spain
University of Navarra Hospital Recruiting
Pamplona, Navarra, Spain, 31008
Principal Investigator: MAURIZIO BENDANDI, MD, PhD         
Sponsors and Collaborators
Clinica Universidad de Navarra, Universidad de Navarra
University of Navarrra Hospital (Clinica Universitaria)
Center for Applied Medical Research (Centro de Investigación Médica Aplicada)
Investigators
Layout table for investigator information
Principal Investigator: MAURIZIO BENDANDI, MD, PhD University of Navarra
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Clinica Universidad de Navarra, Universidad de Navarra
ClinicalTrials.gov Identifier: NCT00530140    
Other Study ID Numbers: CUN-90-2006
First Posted: September 17, 2007    Key Record Dates
Last Update Posted: October 6, 2011
Last Verified: October 2011
Keywords provided by Clinica Universidad de Navarra, Universidad de Navarra:
Follicular Lymphoma
Idiotype vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Follicular
Recurrence
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
 Immune System Diseases
Lymphoma, Non-Hodgkin
Disease Attributes
Pathologic Processes
Immunoglobulin Idiotypes
Immunologic Factors
Physiological Effects of Drugs